The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase III trial of S-1 plus cisplatin versus docetaxel plus cisplatin for advanced non-small-cell lung cancer (TCOG0701).
Nobuyuki Katakami
Honoraria - Bristol-Myers Squibb; Taiho Pharmaceutical
Research Funding - Bristol-Myers Squibb; sanofi-aventis Japan; Taiho Pharmaceutical
Akihiko Gemma
No relevant relationships to disclose
Hiroshi Sakai
No relevant relationships to disclose
Kaoru Kubota
No relevant relationships to disclose
Makoto Nishio
Honoraria - Chugai Pharma
Akira Inoue
No relevant relationships to disclose
Hiroaki Okamoto
No relevant relationships to disclose
Hiroshi Isobe
No relevant relationships to disclose
Hideo Kunitoh
Honoraria - sanofi-aventis Japan; Taiho Pharmaceutical
Yuichi Takiguchi
Honoraria - sanofi-aventis Japan; Taiho Pharmaceutical
Research Funding - sanofi-aventis Japan; Taiho Pharmaceutical
Kunihiko Kobayashi
Honoraria - Taiho Pharmaceutical
Yoichi Nakamura
No relevant relationships to disclose
Hironobu Ohmatsu
No relevant relationships to disclose
Shunichi Sugawara
No relevant relationships to disclose
Koichi Minato
No relevant relationships to disclose
Masaaki Fukuda
No relevant relationships to disclose
Akira Yokoyama
No relevant relationships to disclose
Masahiro Takeuchi
Consultant or Advisory Role - Taiho Pharmaceutical
Hirofumi Michimae
No relevant relationships to disclose
Shoji Kudoh
No relevant relationships to disclose